Clinical Trials Logo

Leukemia, Myelocytic, Acute clinical trials

View clinical trials related to Leukemia, Myelocytic, Acute.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02895412 Recruiting - Clinical trials for Leukemia, Myelocytic, Acute

Infection and Tumour Antigen Cellular Therapy

INTACT-WT1
Start date: August 2016
Phase: Phase 1
Study type: Interventional

This study is to test a new therapy for patients with acute myeloid leukaemia who are undergoing blood stem cell transplant. In this study, the investigators will take a small number of your immune cells whose normal function is to give immunity to infections and help to fight leukaemia. These cells will be stimulated to multiply in the laboratory and will then be given to the transplant recipient after the transplant. This is a sort of "immunity transplant". The exact purpose of this study is to investigate if these cells are safe and effective in patients having a transplant for AML.

NCT ID: NCT01034592 Recruiting - Leukemia Clinical Trials

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

Start date: November 2009
Phase: N/A
Study type: Interventional

This is a single-center, single arm, open-label study of oral lenalidomide monotherapy administered to red blood cell (RBC) transfusion dependent adult subjects with Diamond-Blackfan Anemia (DBA). Primary Objective: To evaluate the erythroid response rate as measured by rate of red blood cell transfusion independence (MDS IWG 2000 Criteria will be applied) Secondary Objective: 1)To evaluate the tolerability and safety profile of lenalidomide in patients with DBA and other inherited marrow failure syndromes 2) To correlate response to lenalidomide with biologic surrogates of DBA including ribosomal protein mutation status, ex vivo erythroid colony growth, and microarray gene expression

NCT ID: NCT00449319 Recruiting - Clinical trials for Leukemia, Myelocytic, Acute

AML Treatment in Untreated Adult Patients

LAM99P
Start date: November 1998
Phase: N/A
Study type: Interventional

The present therapy intends to be an homogeneous treatment for AML patients based on a pretreatment with hydroxiurea plus an induction therapy with the standard arm with Daunorubicine as according to EORTC-GIMEMA AML10 study. The post-remissional treatment is based on transplant with HLA compatible donor is foreseen for all patients and autologous transplant for those without HLA compatible donor available.

NCT ID: NCT00126321 Recruiting - Clinical trials for Leukemia, Myelocytic, Acute

Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

Start date: November 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and the efficacy of cladribine, high-dose cytarabine and idarubicin in the treatment of patients with relapsed acute myeloid leukemia.